Sutro Biopharma discovers, designs and develops novel protein therapeutics. Sutro’s biochemical protein synthesis technology creates protein therapeutics that cannot be produced, or even accessed, using conventional methods. The company is using this technology to introduce specific and unique modifications, including non-natural amino acids, into proteins to generate novel biotherapeutics, and “biosuperiors” with significantly improved pharmaceutical and biological properties. Sutro’s technology enables the rapid and systematic exploration of many protein drug variants to identify true drug candidates. Once identified, production of these protein drug candidates can be rapidly scaled to commercial levels in a GMP manner. In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.
Other investors include: Alta Ventures, Amgen Ventures, Skyline Ventures, and SV Life Sciences.